Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis

Authors: Tania F. Gendron, Jeannie Chew, Jeannette N. Stankowski, Lindsey R. Hayes, Yong‐Jie Zhang, Mercedes Prudencio, Yari Carlomagno, Lillian M. Daughrity, Karen Jansen‐West, Emilie A. Perkerson, Aliesha D. O’Raw, Casey Cook, Luc Pregent, Véronique Belzil, Marka van Blitterswijk, Lilia J. Tabassian, Chris W. Lee, Mei Yue, Jimei Tong, Yuping Song, Monica Castanedes‐Casey, Linda Rousseau, Virginia Phillips, Dennis W. Dickson, Rosa Rademakers, John Denis Fryer, Beth Rush, Otto Pedraza, Ana M. Caputo, Pamela Desaro, Carla Palmucci, A. Robertson, Michael G. Heckman, Nancy N. Diehl, Edythe Wiggs, Michael Tierney, Laura Braun, Jennifer Farren, David Lacomis, Shafeeq Ladha, Christina Fournier, Leo McCluskey, Lauren Elman, Jon B. Toledo, Jennifer D. McBride, Cinzia Tiloca, Claudia Morelli, Barbara Poletti, Federica Solca, A. Prelle, Joanne Wuu, Jennifer Jockel‐Balsarotti, Frank Rigo, Christine Ambrose, Abhishek Datta, Weixing Yang, Denitza Raitcheva, Giovanna Antognetti, Alexander McCampbell, John C. van Swieten, Bruce L. Miller, Adam L. Boxer, Robert H. Brown, Robert Bowser, Timothy M. Miller, John Q. Trojanowski, Murray Grossman, James D. Berry, William T. Hu, Antonia Ratti, Bryan J. Traynor, Matthew D. Disney, Michael Benatar, Vincenzo Silani, Jonathan D. Glass, Mary Kay Floeter, Jeffrey D. Rothstein, Khrista Boylan, Leonard Petrucelli - Science Translational Medicine 2017 cited by 268

Poly(GP) proteins are a promising pharmacodynamic marker for developing and testing therapeutics for treating C9ORF72 -associated amyotrophic lateral sclerosis.